Poppe Christopher, Repantis Dimitris
Department of Psychiatry and Neurosciences, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
German Center for Mental Health (DZPG), Berlin, Potsdam, Germany.
Curr Top Behav Neurosci. 2024 Nov 8. doi: 10.1007/7854_2024_533.
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and at the intersection of psychedelic medicine and society. In contrast to earlier psychedelic research, nowadays medical ethics have been firmly established as a discipline regulating patient-physician relationships which highlight the importance of autonomy, shared decision-making and informed consent in clinical ethics. During and after altered states of consciousness, autonomy is particularly important as participants are in a vulnerable state. In this vulnerable state, both touch and suggestibility are central ethical concerns. In turn, the debate surrounding hallucinogenic and nonhallucinogenic psychedelic substances discusses the importance of altered states of consciousness in general. Of further concern are exceptional training requirements and competencies of psychedelic therapists, as well as the particular context of end-of-life care. Lastly, this section discusses how ethical integrity in clinical treatments can be supported through institutions. In research ethics, inclusivity, research equipoise, and expectation management are key issues in the participation and trials, while open question for the posttrial access to care after psychedelic trials remain. Finally, the chapter addresses the question of equitable access to psychedelic medicine. Furthermore, justice for indigenous communities using psychedelics and the impact of legalization and medicalization of psychedelic substances are pressing ethical concerns amidst the "psychedelic renaissance."
在本章中,我们概述了迷幻辅助治疗在临床伦理、研究伦理以及迷幻医学与社会交叉领域中的伦理问题。与早期的迷幻研究不同,如今医学伦理已牢固确立为一门规范医患关系的学科,强调临床伦理中自主性、共同决策和知情同意的重要性。在意识改变状态期间及之后,自主性尤为重要,因为参与者处于脆弱状态。在这种脆弱状态下,接触和易受暗示性都是核心伦理问题。反过来,围绕致幻和非致幻迷幻物质的辩论总体上讨论了意识改变状态的重要性。此外令人关注的是迷幻治疗师特殊的培训要求和能力,以及临终关怀的特殊背景。最后,本节讨论了如何通过机构来支持临床治疗中的伦理完整性。在研究伦理中,包容性、研究均衡性和期望管理是参与和试验中的关键问题,而迷幻试验后获得护理的试验后问题仍未解决。最后,本章探讨了公平获得迷幻药物的问题。此外,在“迷幻复兴”背景下,使用迷幻剂的土著社区的正义问题以及迷幻物质合法化和医学化的影响是紧迫的伦理关切。